Cision Newshttps://news.cision.comCision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.Tue, 09 Jun 2026 10:16:10 GMTCision News14660https://news.cision.comhttps://news.cision.com/Content/img/news-logo.pngPergamum announces final data from Phase I/II study of LL-37 in patients with chronic leg ulcershttps://news.cision.com/karolinska-development-ab--publ-/r/pergamum-announces-final-data-from-phase-i-ii-study-of-ll-37-in-patients-with-chronic-leg-ulcers,c9479594cision1449128Thu, 10 Oct 2013 06:00:00 GMTKarolinska Development presents today at the 2013 Stifel Healthcare Conference in Bostonhttps://news.cision.com/karolinska-development-ab--publ-/r/karolinska-development-presents-today-at-the-2013-stifel-healthcare-conference-in-boston,c9464728cision1424776Thu, 12 Sep 2013 06:00:00 GMTLipidor reports positive clinical Phase I/II data in psoriasishttps://news.cision.com/karolinska-development-ab--publ-/r/lipidor-reports-positive-clinical-phase-i-ii-data-in-psoriasis,c9456493cision1410187Tue, 27 Aug 2013 06:00:00 GMTPurchase of own shares to cover social security fees related to incentive programhttps://news.cision.com/karolinska-development-ab--publ-/r/purchase-of-own-shares-to-cover-social-security-fees-related-to-incentive-program,c9454885cision1407305Thu, 22 Aug 2013 06:30:00 GMTKarolinska Development AB (publ) ― Interim report January - June 2013https://news.cision.com/karolinska-development-ab--publ-/r/karolinska-development-ab--publ----interim-report-january---june-2013,c9454865cision1407243Thu, 22 Aug 2013 06:00:00 GMTPharmanest meets all efficacy and safety end points in Phase II study of SHACThttps://news.cision.com/karolinska-development-ab--publ-/r/pharmanest-meets-all-efficacy-and-safety-end-points-in-phase-ii-study-of-shact,c9447180cision1393100Thu, 01 Aug 2013 06:00:00 GMTOss-Q completes financing, initiates clinical study and changes name to OssDsignhttps://news.cision.com/karolinska-development-ab--publ-/r/oss-q-completes-financing--initiates-clinical-study-and-changes-name-to-ossdsign,c9441902cision1382916Mon, 15 Jul 2013 06:00:00 GMTPergamum reports positive preliminary efficacy results from a Phase I/II study of LL-37 in patients with chronic leg ulcershttps://news.cision.com/karolinska-development-ab--publ-/r/pergamum-reports-positive-preliminary-efficacy-results-from-a-phase-i-ii-study-of-ll-37-in-patients-,c9438261cision1375956Thu, 04 Jul 2013 06:00:00 GMTKarolinska Development initiates collaborations with Ospedale San Raffaele and Medical University of Grazhttps://news.cision.com/karolinska-development-ab--publ-/r/karolinska-development-initiates-collaborations-with-ospedale-san-raffaele-and-medical-university-of,c9434806cision1369896Thu, 27 Jun 2013 07:00:00 GMTPergamum reports positive follow-up data from a Phase II clinical trial of PXL-01 for prevention of post-surgical adhesionshttps://news.cision.com/karolinska-development-ab--publ-/r/pergamum-reports-positive-follow-up-data-from-a-phase-ii-clinical-trial-of-pxl-01-for-prevention-of-,c9458200cision1369705Thu, 27 Jun 2013 06:00:00 GMTKarolinska Development invests in Forendo Pharmahttps://news.cision.com/karolinska-development-ab--publ-/r/karolinska-development-invests-in-forendo-pharma,c9433397cision1367390Tue, 25 Jun 2013 06:00:00 GMTAthera and Boehringer Ingelheim enter into an option agreement on a novel therapy for Atherosclerosishttps://news.cision.com/karolinska-development-ab--publ-/r/athera-and-boehringer-ingelheim-enter-into-an-option-agreement-on-a-novel-therapy-for-atherosclerosi,c9430694cision1362232Wed, 19 Jun 2013 06:00:00 GMTEU grants EUR 6m to the clinical development of Athera´s cardiovascular disease antibody therapyhttps://news.cision.com/karolinska-development-ab--publ-/r/eu-grants-eur-6m-to-the-clinical-development-of-athera-s-cardiovascular-disease-antibody-therapy,c9429345cision1359719Mon, 17 Jun 2013 06:00:00 GMTFirst patient dosed in the Phase I/II study of Umecrine Mood’s candidate drug for premenstrual dysphoric disorderhttps://news.cision.com/karolinska-development-ab--publ-/r/first-patient-dosed-in-the-phase-i-ii-study-of-umecrine-mood-s-candidate-drug-for-premenstrual-dysph,c9418459cision1339330Thu, 23 May 2013 06:00:00 GMTKarolinska Development´s Annual General Meeting 2013https://news.cision.com/karolinska-development-ab--publ-/r/karolinska-development-s-annual-general-meeting-2013,c9414821cision1331754Wed, 15 May 2013 06:00:00 GMTKarolinska Development AB (publ) - Interim report January - March 2013https://news.cision.com/karolinska-development-ab--publ-/r/karolinska-development-ab--publ----interim-report-january---march-2013,c9412928cision1327855Fri, 10 May 2013 06:00:00 GMTKarolinska Development - Interim report January - March, invitation to conference call Friday, May 10https://news.cision.com/karolinska-development-ab--publ-/r/karolinska-development---interim-report-january---march--invitation-to-conference-call-friday--may-1,c9411040cision1324299Tue, 07 May 2013 06:00:00 GMTPergamum announces last visit of last patient in a Phase I/II trial of a potential new treatment for hard-to-heal woundshttps://news.cision.com/karolinska-development-ab--publ-/r/pergamum-announces-last-visit-of-last-patient-in-a-phase-i-ii-trial-of-a-potential-new-treatment-for,c9403216cision1307748Fri, 19 Apr 2013 06:00:00 GMTKarolinska Development’s Annual Report 2012 has been publishedhttps://news.cision.com/karolinska-development-ab--publ-/r/karolinska-development-s-annual-report-2012-has-been-published,c9400135cision1301594Fri, 12 Apr 2013 14:01:15 GMTNotice of Annual General Meeting of Karolinska Development AB (publ)https://news.cision.com/karolinska-development-ab--publ-/r/notice-of-annual-general-meeting-of-karolinska-development-ab--publ-,c9399868cision1299763Fri, 12 Apr 2013 08:48:57 GMTBo Jesper Hansen proposed as new Chairman of the Boardhttps://news.cision.com/karolinska-development-ab--publ-/r/bo-jesper-hansen-proposed-as-new-chairman-of-the-board,c9398364cision1298438Wed, 10 Apr 2013 06:00:00 GMTPreliminary results of a Phase II study indicates that Axelar’s AXL1717 is efficacious in 2nd line treatment of patients with lung cancerhttps://news.cision.com/karolinska-development-ab--publ-/r/preliminary-results-of-a-phase-ii-study-indicates-that-axelar-s-axl1717-is-efficacious-in-2nd-line-t,c9393504cision1288653Tue, 02 Apr 2013 06:00:00 GMTKarolinska Development and Rosetta Capital Announce the Closing of their SEK 220 Million Strategic Transactionhttps://news.cision.com/karolinska-development-ab--publ-/r/karolinska-development-and-rosetta-capital-announce-the-closing-of-their-sek-220-million-strategic-t,c9382048cision1265771Fri, 08 Mar 2013 07:00:00 GMTKarolinska Development AB (publ) – Year-End Report 2012https://news.cision.com/karolinska-development-ab--publ-/r/karolinska-development-ab--publ----year-end-report-2012,c9373026cision1247472Wed, 20 Feb 2013 07:00:00 GMT